ArticleArquivos de neuro-psiquiatria2026
Parkinson's disease-associated psychosis in a Brazilian sample: prevalence and clinical profile.
Article in Arquivos de neuro-psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psychosis is a frequent and disabling non-motor complication of Parkinson's disease (PD). Reported prevalence varies widely, and data in Brazilian cohorts remain scarce. Objective: To estimate the prevalence of PD-associated psychosis (PDP) in a Brazilian cohort and to describe its sociodemographic and clinical profile. Methods: We conducted a cross-sectional study in a Brazilian movement disorders outpatient clinic between May and December of 2022. Adult patients with idiopathic PD defined by the United Kingdom's Parkinson's Disease Society Brain Bank criteria were consecutively evaluated. Sociodemographic and clinical variables were collected. Psychosis was assessed using the diagnosis criteria proposed by the National Institute of Neurological Disorders and Stroke and the National Institute of Mental Health (NINDS/NIMH) and graded with the Movement Disorders Society's Unified PD Rating Scale (MDS-UPDRS). Cognitive screening was performed using the Mini-Mental State Examination (MMSE), and disease severity was assessed with the modified Hoehn & Yahr scale (mH&Y). Neuropsychiatric symptoms were evaluated with the Neuropsychiatric Inventory Questionnaire (NPI-Q). Descriptive analyses and exploratory univariate comparisons were performed. Results: In total, 75 patients were included. The median age was 68 years (IQR: 59.5-74.5), and the mean age at PD onset was 56.0 ± 9.8 years. Median disease duration was 10 years (IQR: 6-14.5). Most patients were male (54.7%) and self-identified as Mixed-race (48.6%) or Black (31.1%). According to the mH&Y scale, 82.7% had mild-to-moderate disease. Furthermore, PDP was diagnosed in 18 patients (24%) according to NINDS/NIMH criteria. Minor phenomena and hallucinations were the most frequent psychotic manifestations, each occurring in 72.2% of PDP cases. Conclusion: In this Brazilian cohort, PDP had a prevalence of 24%. These findings reinforce that psychosis is a frequent non-motor manifestation of PD and highlight the importance of systematic clinical screening in routine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.